New research reveals that neurons release a little-understood extracellular kinase called VLK to strengthen synaptic ...
Bayer’s Hyrnuo gets US FDA accelerated approval to treat patients with previously treated advanced HER2-mutant NSCLC: Berlin Friday, November 21, 2025, 11:00 Hrs [IST] Following ...
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...
14h
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years ...
In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced the companies have initiated the rolling submission of a New Drug ...
On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...
The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive ...
Cullinan Therapeutics (CGEM) and Otsuka Holdings (OTSKF) subsidiaries Taiho Oncology and Taiho Pharmaceutical have initiated the rolling ...
NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ ...
The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback